Document:

Amendment Number Two to Master Services Agreement

 EXHIBIT 10.4 
 Amendment No. 2 to Master Services Agreement 
 This Amendment Number Two (this “Amendment 2”) is
entered into this 22nd day of April, 2009 (the “Amendment 2 Effective Date”), by and between Antigenics Inc., a Delaware corporation having an address at 162 Fifth Avenue, Suite 900, New York, New York 10010 (the “Company”) and
Raifarm Limited, a Cyprus registered company, having an address at Cyprus- Limassol 3030, 35 Thekla Lysioti street Eagle Star House, 6th floor, (each a “Party” and collectively the “Parties”). Capitalized terms not otherwise
defined shall have the meaning set forth in the Agreement. 
 WHEREAS, Company and Raifarm Limited are parties to that certain Master
Services Agreement with an effective date of May 23, 2007 (as amended from time to time, the “Agreement”); and 
 WHEREAS, the
Parties now wish to amend the Agreement as set forth herein. 
 NOW THEREFORE, and in consideration of the premises and mutual covenants and
agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
  

	 	1.	The Parties acknowledge and agree that the term of the Agreement shall be extended through [**]. 

  

	 	2.	The Parties further acknowledge and agree that, except as set forth in this Amendment 2, the Agreement shall remain in full force and effect. 

  

	 	3.	This Amendment 2 shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, U.S.A. irrespective of any conflicts of law principles thereof.

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit
has been filed separately with the Commission. 

 IN WITNESS WHEREOF, the Parties each have caused this Amendment 2 to be executed by their duly respective
authorized representative as of the Amendment 2 Effective Date. 
  

			
	ANTIGENICS INC., a Delaware corporation
		
	By:	 	/s/ Kerry Wentworth
	Name:	 	Kerry Wentworth
	Title:	 	Vice President Clinical, Regulatory and Quality
	
	Raifarm Limited
		
	By:	 	/s/ Yuri Raifeld
	Name:	 	Yuri Raifeld
	Title:	 	President and CEO

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An
unpredicted version of this exhibit has been filed separately with the Commission.Letter of Agreement with The University of Connecticut Health Center

 EXHIBIT 10.5 
 May 11, 2009 
 Michael F. Newborg, Executive Director 
 University of Connecticut Health Center 
 Center for Science and Technology Commercialization 
 263 Farmington Ave 
 Farmington, CT 06030-6207 
  

	 	Re:	License Agreement between University of Connecticut Health Center (“UConn”) and Antigenics Inc. effective May 25, 2001, as amended (the “Agreement”)

 Dear Dr. Newborg: 
 As you are aware,
Antigenics and UConn have been in good faith negotiations regarding our proposal of a potential [**] in certain annual license fee terms per section 3.1 of the Agreement and an [**] in certain milestone payments per section 3.2. 
 This letter serves to memorialize the parties’ agreement to extend the date for Antigenics to fulfill its obligations under section 3.1 of the Agreement until
June 15, 2009, while the parties continue their current negotiations to amend the terms of the Agreement. 
 All other obligations of the parties under
the Agreement shall remain in force. 
 Please confirm your agreement by kindly signing and returning one fully executed version of this letter to:
Antigenics Inc., 3 Forbes Road, Lexington, MA 02421, Attention: Legal Department. 
  

	
	Sincerely,
	
	/s/ Karen Valentine
	 Karen Valentine
 Vice President and General Counsel

 Acknowledged and Agreed: 
 University of Connecticut Health Center 

			
		
	By:	 	/s/ Michael F. Newborg
	Title:	 	Michael F. Newborg, Executive Director

 Date: 5/11/09 
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission.Amendment Number Two to License Agreement

 EXHIBIT 10.6 
 AMENDMENT – NUMBER TWO 
 LICENSE AGREEMENT 
 This Amendment Number Two (this “Amendment 2”) is entered into this 5th day of June, 2009 by and between the UNIVERSITY OF CONNECTICUT HEALTH
CENTER, having a place of business at the Center for Science and Technology Commercialization, 263 Farmington Avenue, Farmington, Connecticut 06030-6207 (“UCONN”), and ANTIGENICS INC., having offices at 3 Forbes Road, Lexington,
Massachusetts 02421 (“ANTIGENICS”) (each a “Party” and collectively, the “Parties”). 
 WITNESSETH

 WHEREAS, the Parties have entered into a License Agreement dated May 25, 2001, as amended March 18, 2003 (the
“Agreement”); and 
 WHEREAS, the Parties now wish to amend the Agreement as set forth herein; 
 NOW, THEREFORE, the parties agree as follows: 
  

	 	1.	Section 3.1(b) of the Agreement is hereby deleted in its entirety and replaced with the following: 

 (b) Annual License Fee Maintenance. Starting at the fifth (5th) anniversary of the Effective Date, ANTIGENICS shall pay UCONN the following annual license maintenance fees, payable in
advance semi-annually, against which royalties otherwise due UCONN pursuant to Section 3.3 may be credited: 
  

					
	 5th Anniversary:
	  	$	[	**] 
	 6th Anniversary
	  	$	[	**] 
	 7th Anniversary
	  	$	[	**] 
	 8th Anniversary
	  	$	[	**] 
	 9th Anniversary
	  	$	[	**] 
	 10th Anniversary
	  	$	[	**] 
	 11th Anniversary
	  	$	[	**] 
	 12th Anniversary & Each Subsequent Anniversary
	  	$	[	**] 

  

	 	2.	Capitalized terms not otherwise defined herein shall have the meaning set forth in the Agreement. 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

	 	3.	The parties further acknowledge and agree that, except as set forth in this Amendment 2, the Agreement shall remains unchanged and in full force and effect.

  

	 	4.	This Amendment 2 shall be deemed to have been entered into in Connecticut and shall be construed and enforced in accordance with Connecticut law without regard for any choice or
conflict of laws or principle that would result in the applications of the domestic substantive law of any other jurisdiction. 

  

	 	5.	This Amendment 2 may be executed by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall
together constitute one and the same instrument. 

 IN WITNESS WHEREOF, the parties each have caused this Amendment 2 to be
executed by their respective duly authorized representative as of the date first set forth above. 
  

			
	UNIVERSITY OF CONNECTICUT HEALTH CENTER
		
	By:	 	/s/ Michael F. Newborg
	Name:	 	Michael F. Newborg
	Title:	 	Executive Director
	
	ANTIGENICS INC
		
	By:	 	/s/ Garo Armen
	Name:	 	Garo Armen
	Title:	 	CEO

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An
unpredicted version of this exhibit has been filed separately with the Commission.Binding Letter of Intent

 EXHIBIT 10.7 
 Binding Letter of Intent 
 May 24, 2009 
 ISSI-Strategy 
 43, Ryabinovaya St. 
 Moscow, 121471

 Attention: General Director 
 Dear Sir: 
 This binding letter of intent (“Letter”) will confirm our prior discussions regarding Antigenics, Inc. and
ISSI-Strategy (the “Parties”) entering into a distribution arrangement for ISSI-Strategy to distribute Antigenics Inc.’s autologous cancer vaccine, Oncophage® in the Russian Federation, and provide related services (the “Proposed Transaction”). This Letter supersedes any prior letters or discussions
regarding the Proposed Transaction. This Letter is intended to create binding legal and contractual obligations of the Parties with respect to matters set forth herein, and upon the breach by a Party of its obligations in any material respect, the
injured Party shall have such rights and remedies with respect thereto as are available to it under applicable law. 
 1. Definitive Agreement; Binding
Effect. The Parties have engaged in negotiations and reached agreement in principle to enter into one or more agreements (the “Agreement”) to reflect the Proposed Transaction. The terms and conditions attached hereto as Exhibit
A sets forth the agreement of the Parties in principal with respect to the Proposed Transaction, and will form the basis of the Agreement. The Agreement will contain mutually agreeable terms and conditions consistent with this Letter.

 2. Negotiation of Amendment. The Parties shall use commercially reasonable efforts to complete negotiations and execute the Agreement as quickly as
reasonably possible. Until the Agreement is executed, the Parties agree that the provisions of this Letter (including the attached Exhibit A) shall govern their relationship. Upon execution and delivery of the Agreement, this Letter shall be
superseded thereby and the rights and obligations of the Parties with respect to the Proposed Transaction shall thereafter be governed by the Agreement. 
 3. Confidentiality. Each Party acknowledges and agrees that it continues to be bound by the terms of that certain Mutual Confidential Disclosure Agreement between the Parties effective dated April 15, 2009 (the
“Confidentiality Agreement”), as set forth in Exhibit B attached hereto with respect to any Confidential Information (as defined in the Confidentiality Agreement) of the other Party received by it hereunder. 
 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately
with the Commission. 

 4. Expenses. Each Party shall pay its own fees and expenses and those of its agents, advisors, attorneys and
accountants with respect to the negotiation of the Agreement. 
 5. No Other Agreements; No Third Party Beneficiary. The Parties agree that as of this
date there are no oral or written representations, agreements or understandings concerning the subject matter of this Letter or the transactions contemplated herein. No person or entity other than the Parties to this Letter shall have any rights
under this Letter. 
 6. Governing Law; Language. This Letter shall be governed by and construed in accordance with the laws of [**], without regard
to any choice of law principles that would dictate the application of the laws of another jurisdiction. 
 If the foregoing accurately
reflects your understanding, please so indicate by signing a copy of this Letter in the space provided below and returning it to me. 
  

	
	Sincerely yours,
	
	/s/ Garo Armen
	Garo Armen
	Antigenics, Inc.

 Confirmed and agreed to this          day of May, 2009.

			
		
	By:	 	/s/ Alexy Shvets
	Title:	 	General Director

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An
unpredicted version of this exhibit has been filed separately with the Commission. 

 EXHIBIT A 
 Basic Principles for the Agreement 
 1. Parties 
 Antigenics, Inc. (“Antigenics”) 
 ISSI-Strategy (“ISSI”)

 2. Purpose and Scope 
 Agreement for ISSI to distribute Antigenics’ autologous cancer vaccine, Oncophage® (“Product”) in
Russia, and provide related import/export and logistics management and commercialization services. 
 Product will be manufactured and supplied by
Antigenics. 
 ISSI will only sell product to hospitals in Russia pre-approved by Antigenics. 
 ISSI will be responsible for activities related to arranging of export of biomaterials required for Product manufacture (“Biomaterials”), as it is prescribed below, and importing Product and ensuring timely
delivery of Product to hospitals at ISSI’s sole cost and expense in the territory of Russian Federation, including but not limited to: 
  

	 	•	 	 Preparation of required documents for Product import 

  

	 	•	 	 Payment of all custom fees and duties (est. [**] of cost of goods ) and VAT (est. [**] of cost of goods) 

  

	 	•	 	 Payment of all Customs Broker Service fee (est. [**]) 

  

	 	•	 	 Obtaining and holding import Product license (and renew yearly) 

  

	 	•	 	 Obtaining and holding all Customs permissions related to Product import 

  

	 	•	 	 Customs clearance and Product batch certification (to be performed without the box being opened 

  

	 	•	 	 Ensure Product package clears Russia customs for immediate delivery of the Product to hospital 

  

	 	•	 	 Re-icing of the Product with dry ice prior to clearing the bonded warehouse at the airport (if needed) 

  

	 	•	 	 Help arranging a courier for Biomaterial export 

  

	 	•	 	 ISSI can train and assist with the administrative management of the tumor paperwork 

 ISSI will enter into agreements (pre-approved by Antigenics) with hospitals (pre-approved by Antigenics) for the purchase of Product. 
 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 3. Shipping terms 
 Title and risk of loss of Product to transfer to ISSI upon [**] the Product by [**] at the [**]. 
 4.
Initial Pricing 
 ISSI will purchase Product from Antigenics for [**] USD. (This price does not include customs duties or VAT which are payable by ISSI).

 Antigenics will have the right to change the supply price to ISSI for Product after [**] of the agreement. 
 ISSI shall sell the Product to clinics under the price, previously agreed with Antigenics, which will include ISSI expenses for forming all the necessary licenses and
permitions for the Product import, for import customs processing, for all the necessary payments, payment taxes, shipping and storing expenses, advertising expenses, marketing expenses etc. in the territory of the Russian Federation and also
ISSI’s income. 
 The agreement price is defined under the supposed quantity of patients which will use the Product for healing ([**] persons per year).

 The Agreement price is $[**] USD. 
 5.
Payment terms 
 ISSI to pay Antigenics the price for buying Oncophage by wire transfer within [**] days of [**] for the Product. 
 6. Marketing 
 Antigenics and/or its third party
designees retain marketing/promotion responsibilities. 
 7. Exclusivity 
 ISSI to serve as Antigenics’ exclusive distributor for Oncophage in Russia for 3 years. However, Antigenics can render the arrangement non-exclusive or terminate the agreement as set forth in the Termination
provisions below. 
 8. Non-compete 
 During the term of agreement and for a period of [**] thereafter, ISSI will not (1) engage in the business of developing, manufacturing, marketing, providing or distributing: (A) any [**], or (B) any [**], or (2) consult
with, advise or assist in any way, whether or not for consideration, any corporation, limited liability company, partnership, firm or other business organization in developing, manufacturing, marketing, providing, or distributing any of the
following: (A) any [**], or (B) any [**]. 
 9. Compliance 
 ISSI will comply with all applicable laws, rules and regulations, the Agreement, and Antigenics’ standards and procedures. 
 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 10. Term 
 Agreement will have an initial term of 3 years unless extended by mutual agreement or earlier terminated in accordance with the agreement terms. 
 11. Termination 
 ISSI-Strategy can terminate on [**] written notice in the event of the other party’s
(i) bankruptcy, insolvency, or similar filing, or (ii) material breach of the Agreement if not cured within the [**]. Material breach would include without limitation: 
  

	 	a.)	should confidentiality terms be breached; or 

  

	 	b.)	should force majeure circumstances take place that is not cured within [**] 

 Antigenics may terminate the Agreement or render the arrangement non-exclusive upon written notice in the event: 
  

	 	a.)	Antigenics enters into [**]; 

  

	 	b.)	in the event ISSI refuses to place a purchase order for Product where there is a legitimate request for product by an approved center in Russia or sells Product at a price not
agreed to between the Parties or other than to a hospital approved by Antigenics. 

 Otherwise, Antigenics may terminate or render the
arrangement non -exclusive in its entirety for any reason or no reason upon [**] prior written notice. 
 12. Disclaimer 

Given the unique nature of the Product the Agreement will provide that Antigenics can not guarantee that it will be able to successfully manufacture or deliver Product
in any or all circumstances. 
 13. Reference 
 Any dispute, controversy or claim which may arise out of or in connection with the present contract (agreement), or the execution, breach, termination or invalidity thereof, shall be settled by the [**] at the [**] in accordance with its
rules. 
 This Letter shall be governed by and construed in accordance with the laws of [**], without regard to any choice of law principles that would
dictate the application of the laws of another jurisdiction. 
 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment
request. An unpredicted version of this exhibit has been filed separately with the Commission. 

 The present Agreement is prepared in two exemplars both in Russian and in English. The English and Russian versions are
authentic. 
  

			
	 Acknowledged and agreed.
  
 ANTIGENICS INC.

		
	By:	 	/s/ Garo H. Armen
	Name:	 	Garo H. Armen
	Title:	 	CEO
	
	ISSI-STRATEGY
		
	By:	 	/s/ Alexy Shvets
	Name:	 	Alexy Shvets
	Title:	 	General Director

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An
unpredicted version of this exhibit has been filed separately with the Commission. 

 EXHIBIT B 
 See attached Mutual Confidential Disclosure Agreement dated April 19, 2009 between the Parties. 
 [**] = Portions of this exhibit have been
omitted pursuant to a confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]